John P. Hamill - Net Worth and Insider Trading

John P. Hamill Net Worth

The estimated net worth of John P. Hamill is at least $77,212 dollars as of 2024-11-05. John P. Hamill is the SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics Inc and owns about 19,368 shares of Aprea Therapeutics Inc (APRE) stock worth over $76,924. John P. Hamill is the VP Fin,Princ Fin&Acct Officer of Trevena Inc and owns about 132 shares of Trevena Inc (TRVN) stock worth over $233. John P. Hamill is also the SVP & CFO of Windtree Therapeutics Inc and owns about 81 shares of Windtree Therapeutics Inc (WINT) stock worth over $55. Details can be seen in John P. Hamill's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John P. Hamill has not made any transactions after 2024-10-11 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of John P. Hamill

To

John P. Hamill Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John P. Hamill owns 4 companies in total, including Windtree Therapeutics Inc (WINT) , Trevena Inc (TRVN) , and Cellectar Biosciences Inc (CLRB) among others .

Click here to see the complete history of John P. Hamill’s form 4 insider trades.

Insider Ownership Summary of John P. Hamill

Ticker Comapny Transaction Date Type of Owner
WINT Windtree Therapeutics Inc 2022-07-26 SVP & CFO
TRVN Trevena Inc 2019-05-31 Int. Prin. Fin. Off. and PAO
CLRB Cellectar Biosciences Inc 2017-09-05 Interim CFO
LIMIT LIMIT 2024-10-11 SrVP/CFO/Prin. Fin &Acctg. Off

John P. Hamill Latest Holdings Summary

John P. Hamill currently owns a total of 3 stocks. Among these stocks, John P. Hamill owns 19,368 shares of Aprea Therapeutics Inc (APRE) as of October 11, 2024, with a value of $76,924 and a weighting of 99.63%. John P. Hamill owns 132 shares of Trevena Inc (TRVN) as of May 31, 2019, with a value of $233 and a weighting of 0.3%. John P. Hamill also owns 81 shares of Windtree Therapeutics Inc (WINT) as of July 26, 2022, with a value of $55 and a weighting of 0.07%.

Latest Holdings of John P. Hamill

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
APRE Aprea Therapeutics Inc 2024-10-11 19,368 3.97 76,924
TRVN Trevena Inc 2019-05-31 132 1.77 233
WINT Windtree Therapeutics Inc 2022-07-26 81 0.68 55

Holding Weightings of John P. Hamill


John P. Hamill Form 4 Trading Tracker

According to the SEC Form 4 filings, John P. Hamill has made a total of 3 transactions in Aprea Therapeutics Inc (APRE) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Aprea Therapeutics Inc is the acquisition of 50 shares on October 11, 2024, which cost John P. Hamill around $123.

According to the SEC Form 4 filings, John P. Hamill has made a total of 0 transactions in Trevena Inc (TRVN) over the past 5 years. The most-recent trade in Trevena Inc is the acquisition of 12 shares on May 31, 2019, which cost John P. Hamill around $8,700.

According to the SEC Form 4 filings, John P. Hamill has made a total of 4 transactions in Windtree Therapeutics Inc (WINT) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Windtree Therapeutics Inc is the acquisition of 3 shares on July 26, 2022, which cost John P. Hamill around $1,110.

Insider Trading History of John P. Hamill

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

John P. Hamill Trading Performance

GuruFocus tracks the stock performance after each of John P. Hamill's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John P. Hamill is -18.61%. GuruFocus also compares John P. Hamill's trading performance to market benchmark return within the same time period. The performance of stocks bought by John P. Hamill within 3 months outperforms 0 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how John P. Hamill's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of John P. Hamill

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 5 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 15.7 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 13.61 LIMIT LIMIT LIMIT LIMIT LIMIT

John P. Hamill Ownership Network

Ownership Network List of John P. Hamill

No Data

Ownership Network Relation of John P. Hamill

Insider Network Chart

John P. Hamill Owned Company Details

What does Windtree Therapeutics Inc do?

Who are the key executives at Windtree Therapeutics Inc?

John P. Hamill is the SVP & CFO of Windtree Therapeutics Inc. Other key executives at Windtree Therapeutics Inc include director & Chief Executive Officer Craig Fraser , VP & Controller & & CAO Jamie Mcandrew , and 10 percent owner Center Laboratories, Inc. .

Windtree Therapeutics Inc (WINT) Insider Trades Summary

Over the past 18 months, John P. Hamill made no insider transaction in Windtree Therapeutics Inc (WINT). Other recent insider transactions involving Windtree Therapeutics Inc (WINT) include a net purchase of 10,431 shares made by Craig Fraser ,

In summary, during the past 3 months, insiders sold 0 shares of Windtree Therapeutics Inc (WINT) in total and bought 5,431 shares, with a net purchase of 5,431 shares. During the past 18 months, 0 shares of Windtree Therapeutics Inc (WINT) were sold and 5,709 shares were bought by its insiders, resulting in a net purchase of 5,709 shares.

Windtree Therapeutics Inc (WINT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Windtree Therapeutics Inc Insider Transactions

No Available Data

John P. Hamill Mailing Address

Above is the net worth, insider trading, and ownership report for John P. Hamill. You might contact John P. Hamill via mailing address: 4092 New Hope Road, Furlong Pa 18925.